Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurovetenskaper
  • Neurologi
Originalspråkengelska
Sidor (från-till)300-308
TidskriftJournal of Gene Medicine
Volym16
Utgivningsnummer9-10
StatusPublished - 2014
PublikationskategoriForskning
Peer review utfördJa

Nedladdningar

Ingen tillgänglig data